Mycobacterial disease in patients with rheumatic disease (Q37335860)

19 August 2017

title

Mycobacterial disease in patients with rheumatic disease (English)

1 reference

19 August 2017

4

Dick van Soolingen

1 reference

19 August 2017

Jakko van Ingen

1

0 references

Martin J. Boeree

series ordinal

2

object named as

Martin J Boeree

1 reference

19 August 2017

P N Richard Dekhuijzen

series ordinal

3

object named as

P N Richard Dekhuijzen

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Nature Clinical Practice Rheumatology

19 August 2017

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

649-656

1 reference

Serious infections with antirheumatic therapy: are biologicals worse?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Cytokine networks--towards new therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

IL-23 and IL-17 in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Mycobacterium xenopi clinical relevance and determinants, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Clinical relevance of Mycobacterium szulgai in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Reconsidering adjuvant immunotherapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Antirheumatic drugs and the risk of tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Infliximab for rheumatoid arthritis in a patient with tuberculosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0949

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0949

1 reference

19 August 2017

1 reference